ArticleJACC. Asia2025
Effect of Body Mass Index in Patients With Cardiogenic Shock Requiring Microaxial Flow Pump.
Article in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of obesity on mortality in patients with cardiogenic shock (CS) requiring microaxial flow pumps (mAFP) remains undetermined.
objectivesThis study investigated the effect of body mass index (BMI) on mortality in CS patients treated with mAFP.
methodsData from 3,636 consecutive CS patients treated with Impella mAFP in the J-PVAD (Japanese Registry for Percutaneous Ventricular Assist Device) nationwide prospective registry in Japan between February 2020 and December 2022 were analyzed. Patients were stratified into 5 BMI categories: underweight (<18.5 kg/m
resultsCrude 30-day mortality increased incrementally with higher BMI categories. Adjusted HRs for 30-day mortality (normal weight as reference) were 0.71 (95% CI [CI]: 0.56-0.90; P = 0.005) for underweight, 1.03 (95% CI: 0.88-1.21; P = 0.681) for overweight, 1.37 (95% CI: 1.19-1.57; P < 0.001) for obesity, and 2.00 (95% CI: 1.66-2.41; P < 0.001) for severe obesity. Patients in the underweight and severe obesity groups experienced a higher incidence of bleeding after percutaneous coronary intervention under mAFP, whereas hemolysis increased with higher BMI categories. Bleeding and hemolysis were associated with mortality only in patients who were underweight.
conclusionsHigher BMI was associated with increased mortality in CS patients treated with mAFP. Although patients who were underweight demonstrated overall favorable survival outcomes, bleeding and hemolysis contributed to mortality in this group. Further research is needed to explore whether a BMI-based approach can improve clinical outcomes. (Japanese registry for Percutaneous Ventricular Assist Device; UMIN000033603).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.